Novo Nordisk A/S (NYSE:NVO) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have received a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $135.00.

Several research firms have recently weighed in on NVO. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating for the company. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th.

Novo Nordisk A/S Trading Down 2.7%

NVO opened at $64.35 on Tuesday. The firm has a market cap of $288.75 billion, a P/E ratio of 19.56, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a 50-day moving average of $67.31 and a 200 day moving average of $84.38.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Hedge Funds Weigh In On Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in NVO. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after buying an additional 300 shares in the last quarter. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. acquired a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Finally, Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.